Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free SPEC Stock Alerts

INSPECS Group (SPEC) Competitors

INSPECS Group logo
GBX 98.50 +1.50 (+1.55%)
As of 07/3/2026 08:27 AM Eastern
Compare

SPEC vs. TSTL, BVC, AKR, ODX, and CNSL

Should you buy INSPECS Group stock or one of its competitors? MarketBeat compares INSPECS Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with INSPECS Group include Tristel (TSTL), BATM Advanced Communications (BVC), Akers Biosciences (AKR), Omega Diagnostics Group (ODX), and Cambridge Nutritional Sciences (CNSL). These companies are all part of the "medical instruments & supplies" industry.

How does INSPECS Group compare to Tristel?

Tristel (LON:TSTL) and INSPECS Group (LON:SPEC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Tristel has a net margin of 15.88% compared to INSPECS Group's net margin of -2.67%. Tristel's return on equity of 23.64% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Tristel15.88% 23.64% 9.89%
INSPECS Group -2.67%-6.07%0.45%

21.6% of Tristel shares are owned by institutional investors. Comparatively, 0.4% of INSPECS Group shares are owned by institutional investors. 21.0% of Tristel shares are owned by insiders. Comparatively, 21.0% of INSPECS Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Tristel currently has a consensus price target of GBX 400, indicating a potential upside of 0.34%. INSPECS Group has a consensus price target of GBX 60, indicating a potential downside of 39.09%. Given Tristel's higher probable upside, equities research analysts clearly believe Tristel is more favorable than INSPECS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tristel
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Tristel had 1 more articles in the media than INSPECS Group. MarketBeat recorded 1 mentions for Tristel and 0 mentions for INSPECS Group. Tristel's average media sentiment score of 0.00 equaled INSPECS Group'saverage media sentiment score.

Company Overall Sentiment
Tristel Neutral
INSPECS Group Neutral

Tristel has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tristel£49.54M3.86£6.54M£16.2424.55
INSPECS Group£191.70M0.52-£4.11M-£9.40N/A

Tristel has a beta of 0.339, suggesting that its stock price is 66% less volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.607, suggesting that its stock price is 61% more volatile than the broader market.

Summary

Tristel beats INSPECS Group on 11 of the 15 factors compared between the two stocks.

How does INSPECS Group compare to BATM Advanced Communications?

INSPECS Group (LON:SPEC) and BATM Advanced Communications (LON:BVC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

In the previous week, INSPECS Group's average media sentiment score of 0.00 equaled BATM Advanced Communications'average media sentiment score.

Company Overall Sentiment
INSPECS Group Neutral
BATM Advanced Communications Neutral

INSPECS Group presently has a consensus price target of GBX 60, suggesting a potential downside of 39.09%. Given INSPECS Group's stronger consensus rating and higher probable upside, analysts plainly believe INSPECS Group is more favorable than BATM Advanced Communications.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
BATM Advanced Communications
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

BATM Advanced Communications has lower revenue, but higher earnings than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than BATM Advanced Communications, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSPECS Group£191.70M0.52-£4.11M-£9.40N/A
BATM Advanced Communications£123.20M0.40-£278.26K-£4.20N/A

INSPECS Group has a net margin of -2.67% compared to BATM Advanced Communications' net margin of -14.90%. INSPECS Group's return on equity of -6.07% beat BATM Advanced Communications' return on equity.

Company Net Margins Return on Equity Return on Assets
INSPECS Group-2.67% -6.07% 0.45%
BATM Advanced Communications -14.90%-22.13%0.58%

INSPECS Group has a beta of 1.607, suggesting that its stock price is 61% more volatile than the broader market. Comparatively, BATM Advanced Communications has a beta of 0.754, suggesting that its stock price is 25% less volatile than the broader market.

0.4% of INSPECS Group shares are owned by institutional investors. Comparatively, 16.6% of BATM Advanced Communications shares are owned by institutional investors. 21.0% of INSPECS Group shares are owned by insiders. Comparatively, 31.0% of BATM Advanced Communications shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

INSPECS Group beats BATM Advanced Communications on 8 of the 14 factors compared between the two stocks.

How does INSPECS Group compare to Akers Biosciences?

INSPECS Group (LON:SPEC) and Akers Biosciences (LON:AKR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

Akers Biosciences has lower revenue, but higher earnings than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Akers Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSPECS Group£191.70M0.52-£4.11M-£9.40N/A
Akers Biosciences£2.32M0.00N/A-£129.60N/A

In the previous week, INSPECS Group's average media sentiment score of 0.00 equaled Akers Biosciences'average media sentiment score.

Company Overall Sentiment
INSPECS Group Neutral
Akers Biosciences Neutral

0.4% of INSPECS Group shares are held by institutional investors. 21.0% of INSPECS Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Akers Biosciences has a net margin of 0.00% compared to INSPECS Group's net margin of -2.67%. Akers Biosciences' return on equity of 0.00% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
INSPECS Group-2.67% -6.07% 0.45%
Akers Biosciences N/A N/A N/A

INSPECS Group presently has a consensus price target of GBX 60, indicating a potential downside of 39.09%. Given Akers Biosciences' higher possible upside, analysts clearly believe Akers Biosciences is more favorable than INSPECS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Akers Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

INSPECS Group beats Akers Biosciences on 7 of the 11 factors compared between the two stocks.

How does INSPECS Group compare to Omega Diagnostics Group?

INSPECS Group (LON:SPEC) and Omega Diagnostics Group (LON:ODX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

In the previous week, INSPECS Group's average media sentiment score of 0.00 equaled Omega Diagnostics Group'saverage media sentiment score.

Company Overall Sentiment
INSPECS Group Neutral
Omega Diagnostics Group Neutral

INSPECS Group presently has a consensus target price of GBX 60, suggesting a potential downside of 39.09%. Given Omega Diagnostics Group's higher probable upside, analysts clearly believe Omega Diagnostics Group is more favorable than INSPECS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Omega Diagnostics Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

0.4% of INSPECS Group shares are held by institutional investors. Comparatively, 29.8% of Omega Diagnostics Group shares are held by institutional investors. 21.0% of INSPECS Group shares are held by company insiders. Comparatively, 50.6% of Omega Diagnostics Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Omega Diagnostics Group has lower revenue, but higher earnings than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Omega Diagnostics Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSPECS Group£191.70M0.52-£4.11M-£9.40N/A
Omega Diagnostics Group£7.55M0.00-£3.17M-£0.01N/A

INSPECS Group has a beta of 1.607, suggesting that its stock price is 61% more volatile than the broader market. Comparatively, Omega Diagnostics Group has a beta of 3.85, suggesting that its stock price is 285% more volatile than the broader market.

INSPECS Group has a net margin of -2.67% compared to Omega Diagnostics Group's net margin of -51.15%. INSPECS Group's return on equity of -6.07% beat Omega Diagnostics Group's return on equity.

Company Net Margins Return on Equity Return on Assets
INSPECS Group-2.67% -6.07% 0.45%
Omega Diagnostics Group -51.15%-29.14%-10.53%

Summary

INSPECS Group beats Omega Diagnostics Group on 7 of the 13 factors compared between the two stocks.

How does INSPECS Group compare to Cambridge Nutritional Sciences?

Cambridge Nutritional Sciences (LON:CNSL) and INSPECS Group (LON:SPEC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Cambridge Nutritional Sciences has a net margin of 16.94% compared to INSPECS Group's net margin of -2.67%. Cambridge Nutritional Sciences' return on equity of 12.15% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Cambridge Nutritional Sciences16.94% 12.15% -2.36%
INSPECS Group -2.67%-6.07%0.45%

1.6% of Cambridge Nutritional Sciences shares are owned by institutional investors. Comparatively, 0.4% of INSPECS Group shares are owned by institutional investors. 7.8% of Cambridge Nutritional Sciences shares are owned by company insiders. Comparatively, 21.0% of INSPECS Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Cambridge Nutritional Sciences has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Cambridge Nutritional Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cambridge Nutritional Sciences£8.06M0.50-£3.03M£0.602.80
INSPECS Group£191.70M0.52-£4.11M-£9.40N/A

In the previous week, Cambridge Nutritional Sciences' average media sentiment score of 0.00 equaled INSPECS Group'saverage media sentiment score.

Company Overall Sentiment
Cambridge Nutritional Sciences Neutral
INSPECS Group Neutral

INSPECS Group has a consensus price target of GBX 60, indicating a potential downside of 39.09%. Given INSPECS Group's stronger consensus rating and higher probable upside, analysts plainly believe INSPECS Group is more favorable than Cambridge Nutritional Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cambridge Nutritional Sciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Cambridge Nutritional Sciences has a beta of 1.93, meaning that its stock price is 93% more volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.607, meaning that its stock price is 61% more volatile than the broader market.

Summary

Cambridge Nutritional Sciences and INSPECS Group tied by winning 7 of the 14 factors compared between the two stocks.

Get INSPECS Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPEC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SPEC vs. The Competition

Export
MetricINSPECS GroupMedical Instruments & Supplies IndustryMedical SectorLON Exchange
Market Cap£105.90M£3.08B£7.17B£2.74B
Dividend Yield2.00%1.91%2.66%6.15%
P/E Ratio-10.4817.0427.75368.96
Price / Sales0.52109.37535.1785,974.72
Price / Cash1.63146.5429.6527.87
Price / Book0.982.5510.977.75
Net Income-£4.11M£99.80M£3.57B£5.89B
7 Day Performance-1.50%0.91%2.12%0.55%
1 Month Performance16.57%1.55%5.25%-0.34%
1 Year Performance98.99%-6.41%33.29%70.53%

INSPECS Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SPEC
INSPECS Group
N/AGBX 98.50
+1.5%		GBX 60
-39.1%		+104.9%£105.90M£191.70MN/A1,673
TSTL
Tristel
0.6852 of 5 stars		GBX 401.25
+1.8%		GBX 400
-0.3%		-4.2%£192.54M£49.54M24.71208
BVC
BATM Advanced Communications
N/AGBX 14.60
-0.7%		N/A-5.8%£49.65M£123.20MN/A980
AKR
Akers Biosciences
N/AN/AN/AN/A£21.64M£2.32MN/A120
ODX
Omega Diagnostics Group
N/AN/AN/AN/A£5.23M£7.55MN/A91

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:SPEC) was last updated on 7/5/2026 by MarketBeat.com Staff.
From Our Partners
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Porter flew 3,300 miles to investigate this system
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Oil is settling in yuan now - here's what that means for gold
Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...
Golden Portfolio | Sponsoredtc pixel